Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Zolmitriptan

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: Zolmitriptan. Displaying page 1 of 1.
    EudraCT Number: 2007-002654-36 Sponsor Protocol Number: Zomig nasal 5mg/Imigran novum 100mg Start Date*: 2007-10-08
    Sponsor Name:Carl Dahlöf
    Full Title: A randomised prospective open multi-attack study of patient preference and efficacy between zolmitriptan nasal spray 5 mg and sumatriptan RDT 100 mg in the acute treatment of migraine.
    Medical condition: Migraine with and without aura (G 43.0 and G 43.1)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019203-31 Sponsor Protocol Number: D1220C00001 Start Date*: 2011-02-11
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, 4-Armed Parallel Group Study to Evaluate the Efficacy of Zolmitriptan 0.5-, 2.5- and 5-mg Nasal Spray in the Treatment of Acute Migraine...
    Medical condition: Acute Migraine Headache in Adolescents
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066635 Acute migraine LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) EE (Completed) LV (Completed) HU (Completed) PL (Completed) FI (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-004257-14 Sponsor Protocol Number: 0974-011 Start Date*: 2007-02-21
    Sponsor Name:Merck Sharp & Dohme (MSD)
    Full Title: A Multicenter, Double-Blind, Placebo and Active-Controlled, Parallel Group Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo and Zolmitriptan for the Acute Treatment of Migraine...
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027599 Migraine LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-000805-42 Sponsor Protocol Number: MeIn/06/Fro-pp/001 Start Date*: 2007-06-12
    Sponsor Name:Menarini International Operations Luxembourg S.A., Avenue de la Gare, 1611 Luxembourg, Luxembourg
    Full Title: A double-blind, cross-over patient preference study of frovatriptan versus zolmitriptan for the acute treatment of migraine
    Medical condition: Migraine with or without aura according to the IHS criteria
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027599 Migraine LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed) DK (Completed) ES (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002818-16 Sponsor Protocol Number: JM-010CS-OL Start Date*: 2022-12-30
    Sponsor Name:Contera Pharma A/S
    Full Title: Open-Label Extension Study of JM-010 in Parkinson’s Disease Patients With Dyskinesia
    Medical condition: Parkinson's Disease Patients with Dyskinesia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Ongoing) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003415-19 Sponsor Protocol Number: JM-010CS03 Start Date*: 2018-10-31
    Sponsor Name:Contera Pharma
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson’s Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Co...
    Medical condition: Parkinson’s Disease Patients With Moderate to Severe Dyskinesia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Restarted) IT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2019-003646-33 Sponsor Protocol Number: 20190008 Start Date*: 2020-06-24
    Sponsor Name:Amgen, Inc.
    Full Title: Comprehensive Assessment of Erenumab Efficacy in Subjects With High Frequency Episodic Migraine With at Least 1 Previously Failed Preventive Treatment: a Global, Double-blind, Placebo-controlled Ph...
    Medical condition: High frequency episodic migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) PT (Completed) HU (Completed) BG (Completed) CZ (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2006-005764-81 Sponsor Protocol Number: Lumi/06/Fro-Mig/002 Start Date*: 2007-03-21
    Sponsor Name:LUSOFARMACO
    Full Title: FROVATRIPTAN VERSUS ZOLMITRIPTAN IN THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA A PATIENT PREFERENCE STUDY
    Medical condition: Ambulant male and non pregnant females aged 18 and 65 years with history of migraine according to the IHS criteria, having had at least one but not more than six episodes of migraine per month duri...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027599 Migraine LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006574-21 Sponsor Protocol Number: Gui/06/Fro-pp/002 Start Date*: 2007-06-04
    Sponsor Name:GUIDOTTI
    Full Title: A PATIENT PREFERENCE STUDY OF FROVATRIPTAN VERSUS ZOLMITRIPTAN FOR THE ACUTE TREATMENT OF MIGRAINE
    Medical condition: acute migraine
    Disease: Version SOC Term Classification Code Term Level
    6.1 10027599 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 11:27:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA